Developer docs
API playgroundTry for free, no card

Search company profiles

AEROGEN PHARMA

Full company profile

uuid000figq

Namestring
AEROGEN PHARMA
Legal namestring
Aerogen Pharma Limited
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Aerogen Pharma is a clinical-stage specialty pharmaceutical company developing inhaled drug/device combination products for acute and critical care, with a primary focus on AeroFact (APC-0101), an investigational non-invasive pulmonary surfactant therapy for respiratory distress syndrome (RDS) in preterm infants. Its lead program combines Lyomark's Alveofact bovine lung surfactant with the company's proprietary Photo-Defined Aperture Plate (PDAP) vibrating mesh nebulizer, which generates 1–3 μm aerosol droplets synchronized with infant inspiration to enable trans-nasal delivery via nCPAP or non-invasive ventilation without intubation. The PDAP platform is the only system demonstrated to aerosolize high-viscosity, low-surface-tension surfactant formulations, addressing a 60+ year industry failure point.

The company is the drug development arm of the Aerogen Group — the global market leader in hospital aerosol drug delivery with an installed base reaching 16M+ patients across 75 countries — giving it privileged access to a compatible hospital nebulizer hardware footprint and clinical relationships in neonatal intensive care units. Aerogen Pharma is headquartered in Galway, Ireland, with US development operations in San Mateo, California and Morrisville, North Carolina. AeroFact has secured FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations, plus parallel EMA Fast Track and Orphan Drug designations, and is currently in a Phase 2b trial across approximately 42 US and Canadian sites with a pivotal Phase 3 study anticipated in 2025.

The business model is multi-layered: future commercial product sales (post-approval) of combination drug/device products, upfront and milestone-based licensing revenue (exemplified by the 2021 Nuance Pharma Greater China deal worth up to $212.5M+), development services for pharma partners seeking to use the PDAP platform, and grant-funded global health development supported by the Bill & Melinda Gates Foundation for low- and middle-income country deployment. Primary customer segments are hospital NICUs (Level II–IV) for AeroFact adoption and pharmaceutical/biotech partners for PDAP-enabled development programs.

Short descriptiontext

Aerogen Pharma is a clinical-stage specialty pharmaceutical company developing the AeroFact inhaled surfactant and proprietary PDAP vibrating mesh nebulizer platform for non-invasive treatment of respiratory distress syndrome in preterm infants, targeting hospital neonatal ICUs and pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Mateo, United States
HQ citystring
San Mateo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
inhaled drug delivery, neonatal respiratory therapeutics, pulmonary surfactant therapy, aerosolized pharmaceutical products, drug-device combination products
Industry4 codes
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAIAJ
Nebulizers & Aerosol Drug Delivery Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAKANAM
Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical and Medicine Manufacturing3254
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Inhaled Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales (Post-Approval)
TypeOne Time License
Description

Revenue from sales of proprietary inhaled drug/device combination products, primarily AeroFact for neonatal RDS treatment, upon regulatory approval.

aerogenpharma.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Upfront payments, equity stakes, and development/regulatory/commercial milestone payments from partners such as Nuance Pharma ($20M upfront + $10M equity + up to $182.5M milestones + tiered royalties for Greater China rights).

aerogenpharma.com
3Partnership Development Services
TypeProfessional Services
Description

Revenue from consulting and advisory services in aerosol delivery, respiratory care, and regulatory/CMC/clinical aspects of inhaled drug development offered to development partners.

aerogenpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1AeroFact
Description

Phase 3 development program for investigational non-invasive pulmonary surfactant treatment for respiratory distress syndrome in preterm infants.

aerogenpharma.com
+1 more record
Core offering1 text field

Aerogen Pharma develops proprietary inhaled drug/device combination products for acute and critical care, with its lead program AeroFact (APC-0101) delivering non-invasive pulmonary surfactant via the patented PDAP vibrating mesh nebulizer to treat respiratory distress syndrome in preterm infants. The company pairs high-performance aerosol delivery technology with proven therapeutic molecules for hospital-based critical care and offers its PDAP platform for partner-driven development of inhaled NCEs, NBEs, and generics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Ultra-respirable 1-3 μm aerosol droplet size for optimal alveolar deposition
+2 more records
Product overview1 text field

Aerogen Pharma is a clinical-stage specialty pharmaceutical company developing inhaled drug/biologic and device combination products for acute and critical care patients. The company's portfolio centers on AeroFact™ (APC-0101), an investigational non-invasive surfactant replacement therapy for respiratory distress syndrome in preterm infants, which combines a bovine lung surfactant with the proprietary PDAP (Photo-Defined Aperture Plate) vibrating mesh delivery technology. The PDAP platform enables ultra-respirable aerosol generation synchronized with patient inspiration for targeted lung delivery.

Product and service1 record
1AeroFact (APC-0101)
CategoryInhaled Pharmaceutical Product
Description

Investigational biologic/device combination product for non-invasive surfactant replacement therapy to treat respiratory distress syndrome (RDS) in preterm infants. Delivered via nasal CPAP or non-invasive ventilation using a vibrating mesh nebulizer synchronized with infant inspiration. The product combines a bovine lung surfactant (Alveofact) with the proprietary PDAP delivery technology to enable aerosolized surfactant administration without intubation.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-12-22
Description

Exclusive licensing agreement granting Nuance Pharma rights to develop and commercialize AeroFact for RDS treatment in Greater China (Mainland China, Taiwan, Hong Kong, Macau). Aerogen receives $20M upfront, $10M equity in Nuance, potential milestones of $182.5M, plus escalating tiered low double-digit royalties on net sales.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-12-07
Description

Development partnership to create AP-002 inhaled surfactant combining Lyomark's Alveofact (bovine lung surfactant) with Aerogen's PDAP delivery technology. Partners collaborating to commercialize and distribute AP-002 globally. Phase 2 clinical trial initiated in Australia.

Strategic tierCoreTypeTechnology or Integration
Description

Aerogen Pharma is the drug development arm of Aerogen Group. Aerogen Limited is the global market leader in high performance aerosol drug delivery, providing commercial nebulizer technology and distribution infrastructure (16M+ patients in 75 countries).

4The Bill & Melinda Gates Foundation
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Gates Foundation funding to develop Efficient, Safe, Feasible and Cost-Effective surfactant treatment for preterm infants in low- and middle-income countries. Shared goal of reducing infant mortality in resource-limited settings where RDS fatality rates range from 57-89%.

aerogenpharma.com
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Chiesi is a leading manufacturer of pulmonary surfactants (Curosurf) used to treat neonatal RDS — the most direct incumbent competitor Aerogen Pharma will face upon AeroFact approval in NICU formularies worldwide.

TypeDirect peer
Description

AbbVie's Survanta (beractant) is a widely used bovine-derived surfactant for neonatal RDS and a direct competitor to AeroFact's non-invasive delivery of bovine surfactant. Both target the same NICU patient population.

3ONY Biotech (Infasurf)
TypeDirect peer
Description

ONY Biotech markets Infasurf (calfactant), another surfactant approved for neonatal RDS. It is a direct therapeutic competitor whose established relationships with U.S. NICUs AeroFact must overcome.

TypeEmerging player
Description

Verona Pharma develops inhaled respiratory therapeutics (ensifentrine/Ohtuvayre) and shares the drug-device combination product profile in respiratory medicine, with similar late-stage clinical and regulatory execution risk.

TypeOthers
Description

Aerogen Limited is the sister company and global market leader in hospital vibrating-mesh nebulizers. It supplies the underlying aerosol platform technology that Aerogen Pharma extends with PDAP, making it both a critical technology partner and a closely comparable device peer.

TypeBroad incumbent
Description

Vyaire Medical is a global respiratory and ventilation equipment incumbent whose neonatal ventilator and aerosol delivery products overlap with the NICU channel Aerogen Pharma will use for AeroFact distribution.

TypeEmerging player
Description

INHALON Biopharma is an early-stage company developing inhaled therapeutics for respiratory infections using an ion-channel-enabled delivery platform, broadly comparable as a specialty inhaled therapeutics peer targeting critical-care and pulmonary indications.

TypeEmerging player
Description

Savara is a clinical-stage rare respiratory disease company developing inhaled therapies (e.g., molgramostim for aPAP), offering a comparable specialty pharma profile, late-stage clinical execution model, and orphan-drug pathway experience.

TypeRegional player
Description

Lyomark Pharma is the German-based supplier of Alveofact (the bovine surfactant API in AeroFact) and a development partner. While not a direct competitor, it is comparable as a regional specialty respiratory pharma focused on surfactant delivery.

TypeRegional player
Description

Nuance Pharma is the Greater China licensee for AeroFact and a regional specialty pharma player focused on critical care and rare disease, making it a comparable regional commercialization model for AeroFact in Asia.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AEROGEN PHARMA

Inhaled Specialty Pharmaceuticalsaerogenpharma.com

Aerogen Pharma is a clinical-stage specialty pharmaceutical company developing the AeroFact inhaled surfactant and proprietary PDAP vibrating mesh nebulizer platform for non-invasive treatment of respiratory distress syndrome in preterm infants, targeting hospital neonatal ICUs and pharmaceutical partners.

What AEROGEN PHARMA does

Aerogen Pharma is a clinical-stage specialty pharmaceutical company developing inhaled drug/device combination products for acute and critical care, with a primary focus on AeroFact (APC-0101), an investigational non-invasive pulmonary surfactant therapy for respiratory distress syndrome (RDS) in preterm infants. Its lead program combines Lyomark's Alveofact bovine lung surfactant with the company's proprietary Photo-Defined Aperture Plate (PDAP) vibrating mesh nebulizer, which generates 1–3 μm aerosol droplets synchronized with infant inspiration to enable trans-nasal delivery via nCPAP or non-invasive ventilation without intubation. The PDAP platform is the only system demonstrated to aerosolize high-viscosity, low-surface-tension surfactant formulations, addressing a 60+ year industry failure point.

The company is the drug development arm of the Aerogen Group — the global market leader in hospital aerosol drug delivery with an installed base reaching 16M+ patients across 75 countries — giving it privileged access to a compatible hospital nebulizer hardware footprint and clinical relationships in neonatal intensive care units. Aerogen Pharma is headquartered in Galway, Ireland, with US development operations in San Mateo, California and Morrisville, North Carolina. AeroFact has secured FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations, plus parallel EMA Fast Track and Orphan Drug designations, and is currently in a Phase 2b trial across approximately 42 US and Canadian sites with a pivotal Phase 3 study anticipated in 2025.

The business model is multi-layered: future commercial product sales (post-approval) of combination drug/device products, upfront and milestone-based licensing revenue (exemplified by the 2021 Nuance Pharma Greater China deal worth up to $212.5M+), development services for pharma partners seeking to use the PDAP platform, and grant-funded global health development supported by the Bill & Melinda Gates Foundation for low- and middle-income country deployment. Primary customer segments are hospital NICUs (Level II–IV) for AeroFact adoption and pharmaceutical/biotech partners for PDAP-enabled development programs.

AEROGEN PHARMA firmographics

Firmographics
Name
AEROGEN PHARMA
Legal name
Aerogen Pharma Limited
Website
https://aerogenpharma.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Aerogen Pharma is a clinical-stage specialty pharmaceutical company developing the AeroFact inhaled surfactant and proprietary PDAP vibrating mesh nebulizer platform for non-invasive treatment of respiratory distress syndrome in preterm infants, targeting hospital neonatal ICUs and pharmaceutical partners.
Ownership category
akta.pro rank

AEROGEN PHARMA industry classification

Industry
Product category
Inhaled Specialty Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254), Medical Equipment and Supplies Manufacturing (3391)
SIC
Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAIAJ
Nebulizers & Aerosol Drug Delivery Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAKANAM
Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management

Keywords

  • Inhaled drug delivery
  • Neonatal respiratory therapeutics
  • Pulmonary surfactant therapy
  • Aerosolized pharmaceutical products
  • Drug-device combination products

Where AEROGEN PHARMA is headquartered

Location

Headquarters

HQ city
San Mateo
HQ country
United States
HQ region
North America

Offices3 records

Markets served

AEROGEN PHARMA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Product Sales (Post-Approval): Revenue from sales of proprietary inhaled drug/device combination products, primarily AeroFact for neonatal RDS treatment, upon regulatory approval.
  2. Licensing and Milestone Payments: Upfront payments, equity stakes, and development/regulatory/commercial milestone payments from partners such as Nuance Pharma ($20M upfront + $10M equity + up to $182.5M milestones + tiered royalties for Greater China rights).
  3. Partnership Development Services: Revenue from consulting and advisory services in aerosol delivery, respiratory care, and regulatory/CMC/clinical aspects of inhaled drug development offered to development partners.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

AEROGEN PHARMA product offering

Product offering

Core offering

Aerogen Pharma develops proprietary inhaled drug/device combination products for acute and critical care, with its lead program AeroFact (APC-0101) delivering non-invasive pulmonary surfactant via the patented PDAP vibrating mesh nebulizer to treat respiratory distress syndrome in preterm infants. The company pairs high-performance aerosol delivery technology with proven therapeutic molecules for hospital-based critical care and offers its PDAP platform for partner-driven development of inhaled NCEs, NBEs, and generics.

Product overview

Aerogen Pharma is a clinical-stage specialty pharmaceutical company developing inhaled drug/biologic and device combination products for acute and critical care patients. The company's portfolio centers on AeroFact™ (APC-0101), an investigational non-invasive surfactant replacement therapy for respiratory distress syndrome in preterm infants, which combines a bovine lung surfactant with the proprietary PDAP (Photo-Defined Aperture Plate) vibrating mesh delivery technology. The PDAP platform enables ultra-respirable aerosol generation synchronized with patient inspiration for targeted lung delivery.

Differentiator

Problem solved

Functional benefit

Brands

  • AeroFact: Phase 3 development program for investigational non-invasive pulmonary surfactant treatment for respiratory distress syndrome in preterm infants.
  • PDAP (Photo-Defined Aperture Plate)

Products and services

  • AeroFact (APC-0101) Investigational biologic/device combination product for non-invasive surfactant replacement therapy to treat respiratory distress syndrome (RDS) in preterm infants. Delivered via nasal CPAP or non-invasive ventilation using a vibrating mesh nebulizer synchronized with infant inspiration. The product combines a bovine lung surfactant (Alveofact) with the proprietary PDAP delivery technology to enable aerosolized surfactant administration without intubation.

Quantifiable outcome

  • Ultra-respirable 1-3 μm aerosol droplet size for optimal alveolar deposition
  • +2 more outcomes

Companies that use AEROGEN PHARMA

Customer profile

Segments3 records

Ideal customer profiles3 records

AEROGEN PHARMA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

AEROGEN PHARMA partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and flagship.

  • Nuance PharmacoreStrategic or Co-development Partner · 22 December 2021Exclusive licensing agreement granting Nuance Pharma rights to develop and commercialize AeroFact for RDS treatment in Greater China (Mainland China, Taiwan, Hong Kong, Macau). Aerogen receives $20M upfront, $10M equity in Nuance, potential milestones of $182.5M, plus escalating tiered low double-digit royalties on net sales.
  • Lyomark PharmacoreStrategic or Co-development Partner · 7 December 2017Development partnership to create AP-002 inhaled surfactant combining Lyomark's Alveofact (bovine lung surfactant) with Aerogen's PDAP delivery technology. Partners collaborating to commercialize and distribute AP-002 globally. Phase 2 clinical trial initiated in Australia.
  • Aerogen Limited (Sister Company)coreTechnology or IntegrationAerogen Pharma is the drug development arm of Aerogen Group. Aerogen Limited is the global market leader in high performance aerosol drug delivery, providing commercial nebulizer technology and distribution infrastructure (16M+ patients in 75 countries).
  • The Bill & Melinda Gates FoundationflagshipStrategic or Co-development PartnerGates Foundation funding to develop Efficient, Safe, Feasible and Cost-Effective surfactant treatment for preterm infants in low- and middle-income countries. Shared goal of reducing infant mortality in resource-limited settings where RDS fatality rates range from 57-89%.

Scale indicators2 records

Recent moves2 records

Expansion highlights6 records

AEROGEN PHARMA competitors and assessment

Company assessment

Direct peers

  • Chiesi Farmaceutici: Chiesi is a leading manufacturer of pulmonary surfactants (Curosurf) used to treat neonatal RDS — the most direct incumbent competitor Aerogen Pharma will face upon AeroFact approval in NICU formularies worldwide.
  • AbbVie / Abbott (Survanta): AbbVie's Survanta (beractant) is a widely used bovine-derived surfactant for neonatal RDS and a direct competitor to AeroFact's non-invasive delivery of bovine surfactant. Both target the same NICU patient population.
  • ONY Biotech (Infasurf): ONY Biotech markets Infasurf (calfactant), another surfactant approved for neonatal RDS. It is a direct therapeutic competitor whose established relationships with U.S. NICUs AeroFact must overcome.

Emerging players

  • Verona Pharma: Verona Pharma develops inhaled respiratory therapeutics (ensifentrine/Ohtuvayre) and shares the drug-device combination product profile in respiratory medicine, with similar late-stage clinical and regulatory execution risk.
  • INHALON Biopharma: INHALON Biopharma is an early-stage company developing inhaled therapeutics for respiratory infections using an ion-channel-enabled delivery platform, broadly comparable as a specialty inhaled therapeutics peer targeting critical-care and pulmonary indications.
  • Savara Inc. Savara is a clinical-stage rare respiratory disease company developing inhaled therapies (e.g., molgramostim for aPAP), offering a comparable specialty pharma profile, late-stage clinical execution model, and orphan-drug pathway experience.

Others

  • Aerogen Limited: Aerogen Limited is the sister company and global market leader in hospital vibrating-mesh nebulizers. It supplies the underlying aerosol platform technology that Aerogen Pharma extends with PDAP, making it both a critical technology partner and a closely comparable device peer.

Broad incumbents

  • Vyaire Medical: Vyaire Medical is a global respiratory and ventilation equipment incumbent whose neonatal ventilator and aerosol delivery products overlap with the NICU channel Aerogen Pharma will use for AeroFact distribution.

Regional players

  • Lyomark Pharma: Lyomark Pharma is the German-based supplier of Alveofact (the bovine surfactant API in AeroFact) and a development partner. While not a direct competitor, it is comparable as a regional specialty respiratory pharma focused on surfactant delivery.
  • Nuance Pharma: Nuance Pharma is the Greater China licensee for AeroFact and a regional specialty pharma player focused on critical care and rare disease, making it a comparable regional commercialization model for AeroFact in Asia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

AEROGEN PHARMA social profiles

Digital presence

AEROGEN PHARMA compliance and trust

Trust signal

Compliance4 records

AEROGEN PHARMA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AEROGEN PHARMA leadership team

Management profile

Number of profiles

Profiles7 records

AEROGEN PHARMA funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AEROGEN PHARMA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AEROGEN PHARMA

What does AEROGEN PHARMA do?

Aerogen Pharma develops proprietary inhaled drug/device combination products for acute and critical care, with its lead program AeroFact (APC-0101) delivering non-invasive pulmonary surfactant via the patented PDAP vibrating mesh nebulizer to treat respiratory distress syndrome in preterm infants. The company pairs high-performance aerosol delivery technology with proven therapeutic molecules for hospital-based critical care and offers its PDAP platform for partner-driven development of inhaled NCEs, NBEs, and generics.

Is AEROGEN PHARMA a public or private company?

AEROGEN PHARMA is a private company. It is classified as corporate owned and is currently operating.

When was AEROGEN PHARMA founded?

AEROGEN PHARMA was founded in 2015. It employs 11 to 50 people.

Where is AEROGEN PHARMA based?

AEROGEN PHARMA is headquartered in San Mateo, United States, in the North America region.

How does AEROGEN PHARMA make money?

Three revenue lines are on record. Product Sales (Post-Approval) is the primary driver. The others are licensing and Milestone Payments and partnership Development Services.

Who are AEROGEN PHARMA's main competitors?

Direct peers on record are Chiesi Farmaceutici, AbbVie / Abbott (Survanta) and ONY Biotech (Infasurf). Emerging players are Verona Pharma, INHALON Biopharma and Savara Inc.. Aerogen Limited is listed as an others. Vyaire Medical is listed as a broad incumbent. Regional players are Lyomark Pharma and Nuance Pharma.

Does AEROGEN PHARMA have an API?

No public API is recorded for AEROGEN PHARMA.

What industry is AEROGEN PHARMA in?

AEROGEN PHARMA's product category is Inhaled Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAHAGAE, Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories). Its NAICS code is 32541 and its SIC code is 5047.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The News JournalAerogen Pharma modernises quality document control for SharePointAerogen Pharma, a San Mateo-based biopharmaceutical company developing inhaled treatments, has implemented Policy Express for SharePoint to modernize controlled document management and training acknowledgments within Microsoft 365. The 90-day deployment replaced paper-based approvals and wet signatures with digital workflows, enabling 91% of staff to confirm training completion within two weeks and achieving 100% compliance shortly after. Daniel Burgess, Strategic Quality Leader at Aerogen Pharma, noted the improved visibility and audit trail capabilities enabled by the system as key improvements over their previous paper-based processes.Progress-indexAerogen Pharma modernises quality document control for SharePointAerogen Pharma, a San Mateo-based biopharmaceutical company developing inhaled treatments, has implemented Policy Express for SharePoint to modernize controlled document management and training acknowledgments within Microsoft 365, replacing paper-based approvals and wet signatures with structured digital workflows. The company configured, validated, and rolled out the solution within a 90-day window, achieving 91% staff training acknowledgment within two weeks and 100% shortly after, strengthening audit readiness and reducing manual administration for Quality teams.PR NewswireAerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in ChinaAerogen Pharma and Nuance Pharma announced an exclusive license agreement granting Nuance rights to develop and commercialize AeroFact for treating Respiratory Distress Syndrome in premature infants across Greater China. Aerogen Pharma will receive $20 million upfront, $10 million in equity, and up to $182.5 million in potential milestone payments plus tiered royalties. The partnership targets the world's largest surfactant market, offering a non-invasive alternative to conventional invasive surfactant treatment methods for preterm infants.PR NewswireAerogen Pharma and Lyomark Pharma Partner to Develop Inhaled Surfactant, Begin a Phase 2 Clinical TrialAerogen Pharma and Lyomark Pharma have partnered to develop AP-002, an inhaled surfactant treatment for Respiratory Distress Syndrome in preterm infants, combining Lyomark's Alveofact® with Aerogen's proprietary PDAP™ delivery technology. The companies have initiated a Phase 2 clinical trial at three major maternity hospitals in Australia, with results expected mid-2018. The treatment aims to reduce the need for sedation, invasive intubation and mechanical ventilation associated with current surfactant administration methods.